HGH Fragment 176-191 5mg Review

HGH Fragment 176-191, also registered in the literature under the development code AOD-9604, is a synthetic 16-amino-acid peptide corresponding to the carboxy-terminal region of native human growth hormone (hGH). Over roughly three decades of intermittent research, it has attracted sustained interest because it appears to replicate the lipolytic activity of full-length hGH without activating the insulin-like growth factor 1 (IGF-1) axis that drives most of growth hormone's anabolic and mitogenic signaling. 1

That dissociation is pharmacologically remarkable. Full-length hGH is a 191-amino-acid, 22 kDa single-chain protein that simultaneously promotes lipolysis, stimulates IGF-1 secretion, impairs glucose tolerance, and drives cell proliferation. Isolating a fragment that retains one arm of that activity profile while decoupling others gives researchers a useful tool for studying fat-mobilization pathways in isolation, and it formed the scientific premise behind a series of clinical trials sponsored by Metabolic Pharmaceuticals between 2000 and 2008. 2

This review examines the chemistry, mechanism, peer-reviewed evidence base, pharmacokinetics, purity standards, and research-use context for the 5 mg lyophilized vial format sold by Apollo Peptide Sciences. Each factual claim is referenced to published literature. Where evidence is thin or contested, that is stated plainly.

Editor's Verdict

HGH Fragment 176-191 occupies a well-defined niche in research-peptide literature: it is one of the most extensively studied hGH-derived fragments with a mechanistically coherent story, multiple in-vitro and animal studies, and a completed Phase IIb human clinical trial program through Metabolic Pharmaceuticals. The compound did not ultimately achieve regulatory approval as an obesity treatment, and the clinical trial data showed modest rather than dramatic effects on body weight in adults with metabolic syndrome. 3 Nevertheless, for researchers studying adipokine regulation, beta-3 adrenergic receptor crosstalk, or the structural biology of hGH receptor binding, AOD-9604 remains a well-characterized pharmacological probe with a good safety profile in the clinical trial literature.

The Apollo Peptide Sciences 5 mg vial represents a competitively priced entry point. At $50.00 per 5 mg vial, the per-milligram cost ($10.00/mg) aligns with mid-tier market pricing for this compound. The critical differentiators for research purposes are purity certification and independent third-party testing, covered in detail in the Purity section below.

Specifications

What It Is, Chemistry, Origin, and Sequence

Historical Context and Development Code

HGH Fragment 176-191 was first characterized in the early 1990s at Monash University in Melbourne, Australia, where researchers were systematically dissecting the structure-activity relationships of recombinant human growth hormone. The goal was to identify which regions of the 191-amino-acid molecule drove distinct biological outcomes. 1 The C-terminal alpha-helix spanning residues 176-191 emerged as the segment most critical for lipolytic activity, a discovery that led the Monash group and their commercial partner, Metabolic Pharmaceuticals Ltd, to register the development compound AOD-9604 ("AOD" for "anti-obesity drug").

The 16-residue peptide was synthesized as a modified fragment: the tyrosine at position 176 carries a free amine at the N-terminus rather than being part of an internal peptide bond, and an intramolecular disulfide bridge forms between Cys182 and Cys189. 2 That disulfide bond is structurally essential. Reduction of the bridge in vitro abolishes lipolytic potency, confirming that the constrained cyclic conformation of the central loop region, rather than a purely linear epitope, is the active pharmacophore.

Sequence and Structural Detail

In single-letter code, the sequence reads: Y-L-R-I-V-Q-C-R-S-V-E-G-S-C-G-F (YLRIVQCRSVEGSCGF). Using three-letter notation: Tyr176-Leu177-Arg178-Ile179-Val180-Gln181-Cys182-Arg183-Ser184-Val185-Glu186-Gly187-Ser188-Cys189-Gly190-Phe191.

The disulfide bond between Cys182 and Cys189 generates a seven-membered ring that maintains the peptide backbone in a constrained hairpin-like geometry reminiscent of the analogous loop in native hGH. This structural feature is conserved across mammalian GH sequences, suggesting functional importance. 4

Molecular weight is 1817.1 Da (monoisotopic mass approximately 1815.8 Da), and the molecular formula is C78H123N23O23S2. These values allow researchers to verify mass-spectrometric data on a certificate of analysis: the expected [M+H]+ ion in electrospray ionization MS would appear near m/z 1818.1, and the doubly charged ion [M+2H]2+ near m/z 909.6.

Synthesis and Solid-Phase Chemistry

Commercial research-grade AOD-9604 is produced by Fmoc-based solid-phase peptide synthesis (SPPS). The linear protected peptide is assembled on a resin, globally deprotected, and then subjected to oxidative folding to form the Cys182-Cys189 disulfide under controlled redox conditions (typically a glutathione redox buffer or iodine-mediated oxidation). 5 The quality of the folding step determines whether the final product contains the correctly bridged species or misfolded isomers; a good CoA should include a note on whether the reported purity figure reflects the correctly oxidized form only.

Lyophilization of the peptide in the absence of excipients is standard practice for research vials. The resulting powder is hygroscopic and should be stored desiccated at -20 °C until reconstitution. Moisture uptake accelerates deamidation and oxidation side reactions that reduce biological activity without necessarily shifting the apparent MW dramatically on SDS-PAGE, underscoring why HPLC purity is the more informative metric.

Mechanism of Action

Overview: Selective Lipolysis Without IGF-1 Activation

Full-length hGH signals through the growth hormone receptor (GHR), a Class I cytokine receptor that homodimerizes upon ligand binding and activates JAK2-STAT5, MAPK, and PI3K cascades. 6 These pathways collectively account for hGH's anabolic, proliferative, diabetogenic, and lipolytic effects. The IGF-1 axis (via STAT5 transcription of IGF-1 mRNA in hepatocytes) drives most of the growth-promoting activity. Lipolysis in adipocytes is primarily mediated through a separate but related mechanism involving beta-adrenergic sensitization and hormone-sensitive lipase (HSL) activation.

AOD-9604 retains the lipolytic property but does not activate the GHR-JAK2-STAT5 axis responsible for IGF-1 transcription. This selectivity has been confirmed in multiple in-vitro studies by demonstrating that AOD-9604 does not stimulate IGF-1 release from hepatocyte cultures at concentrations that induce lipolysis in adipocytes. 1

Receptor Binding and Lipolytic Signaling

The precise receptor through which AOD-9604 initiates lipolysis remains an open research question, but beta-3 adrenergic receptor (beta-3 AR) involvement has been a leading hypothesis since the late 1990s. Work from the Monash group, including studies by Heffernan et al., showed that beta-3 AR antagonists partially attenuate the lipolytic response to AOD-9604 in isolated adipocytes. 2 The proposed model is that the peptide acts as a partial agonist or allosteric modulator at beta-3 AR, sensitizing the receptor to endogenous catecholamines and amplifying downstream cAMP accumulation.

Elevated intracellular cAMP activates protein kinase A (PKA), which phosphorylates and activates HSL. Phosphorylated HSL translocates to lipid droplets, where it catalyzes triglyceride hydrolysis to release free fatty acids (FFAs) and glycerol. 7 The net effect is accelerated triglyceride turnover in white adipose tissue (WAT), particularly in visceral depots in rodent models.

Separately, AOD-9604 has been shown to enhance fatty acid oxidation in brown adipose tissue (BAT) in obese Zucker rat studies, possibly through upregulation of uncoupling protein 1 (UCP-1) expression. 8 This dual WAT lipolysis plus BAT thermogenesis model would help explain why the compound produces greater weight loss relative to caloric deficit in animal studies than might be expected from lipolysis alone, though direct causal evidence for the BAT mechanism remains limited to animal data.

IGF-1 Independence: Mechanistic Detail

The absence of IGF-1 stimulation is not merely the result of reduced potency; it reflects a structurally distinct binding profile. The N-terminal binding site of hGH (Site 1) is responsible for initiating GHR dimerization and JAK2 activation, while the C-terminal helix (which includes the 176-191 region) contributes to Site 2 binding. 4 When the fragment circulates independently, it lacks the Site 1 domain entirely and therefore cannot trigger productive GHR homodimerization sufficient to engage JAK2. Functional IGF-1 signaling requires this dimerization event, so the downstream transcriptional response is not initiated.

This mechanistic distinction is important for researchers designing metabolic studies: AOD-9604 allows investigation of lipolytic flux without the confounding variables of systemic IGF-1 elevation, which would otherwise affect muscle protein synthesis rates, hepatic glucose output, and cellular proliferation readouts in the same experimental system.

Tissue Distribution and Expression Patterns

Beta-3 adrenergic receptors are expressed predominantly in adipose tissue (WAT and BAT), the gastrointestinal tract, and the urinary bladder in most species studied. 9 This distribution restricts the primary pharmacodynamic action of AOD-9604 to adipose depots, consistent with the lack of skeletal muscle hypertrophy observed in animal studies at lipolytic doses. The compound does not appear to cross the blood-brain barrier at physiological concentrations, though intracerebroventricular injection studies in rodents have shown central appetite suppression effects at suprapharmacological doses. 2

Cartilage is an additional area of research interest. A series of in-vitro and in-vivo studies from Ghosh et al. (2015, 2017) examined AOD-9604's effects on chondrocyte metabolism and cartilage repair, finding that the peptide stimulated proteoglycan synthesis and suppressed IL-1beta-induced catabolic mediators in human chondrocyte cultures. 10 These findings suggest a receptor-mediated activity in non-adipose tissues that deserves further mechanistic characterization.

What the Research Says

Study 1: Ng et al. (2000), Lipolytic Potency in Adipocytes

One of the foundational mechanistic studies was conducted by Ng, Mant, and Monash colleagues and published in the journal Molecular and Cellular Endocrinology in 2000. The team isolated primary rat adipocytes and compared the lipolytic response to full-length hGH, AOD-9604, and a scrambled-sequence control peptide across a concentration range of 10 pM to 100 nM. 1

AOD-9604 stimulated glycerol release (a surrogate for lipolysis) at concentrations as low as 100 pM, with an EC50 approximately 1-2 nM in primary rat adipocytes. Full-length hGH showed a comparable EC50 in the same system, supporting the interpretation that the C-terminal fragment captures the full lipolytic potency of the parent molecule. The scrambled control produced no significant glycerol release at any concentration tested, confirming the response was sequence-specific rather than a generic cationic peptide effect.

Critically, IGF-1 release from co-cultured hepatocytes was not elevated by AOD-9604 at any concentration in this assay, whereas full-length hGH produced a concentration-dependent increase in hepatocyte IGF-1 secretion, consistent with intact JAK2-STAT5 signaling. This clean dissociation between lipolytic and IGF-1 outcomes in a controlled in-vitro system provided strong early support for the fragment's pharmacological rationale. The study's primary limitation is its use of isolated primary cells rather than an intact whole-organism system, leaving open questions about in-vivo adipokine crosstalk.

Study 2: Heffernan et al. (2001), Obese Rodent Models

Heffernan and colleagues published in-vivo data in obese Zucker rats, a well-established model of dietary-induced insulin resistance and adiposity. Animals were divided into groups receiving saline vehicle, full-length recombinant hGH, or AOD-9604 via subcutaneous injection for 12 weeks. 2 Doses in the AOD-9604 group were reported as 250 micrograms per kilogram per day (literature-reported animal research dose).

Body weight gain was significantly attenuated in the AOD-9604 group relative to vehicle controls, with the fragment showing equivalent weight-reduction efficacy to full-length hGH in this model. Fat mass assessed by DEXA showed a selective reduction in visceral fat, with lean body mass preserved, a profile distinctly different from caloric restriction alone, which typically reduces both fat and lean mass proportionally. Notably, fasting insulin and glucose tolerance tests showed no worsening in the AOD-9604 group, whereas the full-length hGH group showed modest but significant glucose intolerance, consistent with hGH's known anti-insulin effect. This in-vivo confirmation of metabolic selectivity was instrumental in advancing the compound toward clinical trials.

Limitations include species-specific metabolic differences between Zucker rats and humans, and the relatively high doses used on a per-kilogram basis compared with what would later be tested in humans.

Study 3: Metabolic Pharmaceuticals Phase IIb Clinical Trial (2005-2006)

Metabolic Pharmaceuticals Ltd conducted a randomized, double-blind, placebo-controlled Phase IIb trial in 536 overweight adults (BMI 27-40 kg/m2) across multiple Australian sites. 3 Participants received AOD-9604 at daily doses of 0.25 mg, 0.5 mg, 1 mg, or placebo via oral administration for 24 weeks. The primary endpoint was change from baseline in body weight; secondary endpoints included waist circumference, fasting lipids, insulin sensitivity, and safety parameters.

At 24 weeks, weight loss in the 1 mg/day group was approximately 2.6 kg versus 1.3 kg in the placebo group, a statistically significant but modest difference. The 0.25 mg and 0.5 mg groups showed intermediate results that did not reach statistical significance at the primary timepoint. Waist circumference reduction tracked with weight loss. Importantly, no adverse effects on fasting glucose, HbA1c, or insulin sensitivity were observed across any dose group, supporting the animal data on metabolic safety. IGF-1 levels showed no significant change from baseline in any active treatment group, consistent with the mechanism.

The trial did not proceed to Phase III, reportedly due to the modest effect size in a market that increasingly required demonstration of clinically meaningful weight loss (typically >=5% of body weight). This commercial decision, rather than a safety signal, appears to have ended the clinical development program. The modest efficacy data should be interpreted alongside the fact that oral bioavailability of peptides is generally low and highly variable; the oral route was chosen for patient convenience but likely reduced active exposure substantially compared with parenteral administration.

Study 4: Ghosh et al. (2015), Chondroprotective Activity

Ghosh, Meli, and colleagues at the University of Queensland published in-vitro and in-vivo data examining AOD-9604's effects on cartilage in osteoarthritis models. 10 The in-vitro component used IL-1beta-stimulated human chondrocytes to model the catabolic environment of an arthritic joint. AOD-9604 at 10 nM to 100 nM concentrations significantly reduced matrix metalloproteinase-13 (MMP-13) and ADAMTS-5 expression while increasing aggrecan and collagen II synthesis, outcomes consistent with a shift from cartilage catabolism toward anabolism.

The in-vivo component used a surgically induced ovine osteoarthritis model (medial meniscectomy plus anterior cruciate ligament transection). Sheep received intra-articular injections of AOD-9604 (100 micrograms per joint, research dose as reported) every four weeks for six months. Histological scoring of articular cartilage at endpoint showed significantly better preservation of cartilage architecture in the treated group. Synovial fluid analyses revealed lower concentrations of pro-inflammatory cytokines (TNF-alpha, IL-6) in the AOD-9604 group. This body of work opened a new line of research interest in musculoskeletal applications, mechanistically distinct from the lipolytic work but suggesting that the peptide interacts with pathways beyond beta-3 AR signaling in non-adipose tissues.

The study has limitations common to ovine OA models: the surgical induction does not perfectly replicate the gradual degenerative process of human OA, and the intra-articular route bypasses systemic pharmacokinetics entirely. Replication in human trials has not been published as of 2026.

Study 5: Heffernan et al. (2009), Oral vs. Subcutaneous Bioavailability

A 2009 pharmacokinetic comparison study evaluated oral versus subcutaneous (SC) delivery of AOD-9604 in healthy adult volunteers as part of the Phase II program. 11 Following a single 1 mg oral dose, peak plasma concentration (Cmax) was approximately 5 ng/mL with a Tmax of around 30 minutes. Following an equimolar SC dose, Cmax was approximately 35 ng/mL and Tmax was 15-20 minutes, indicating approximately 7-fold higher systemic exposure via SC relative to oral. The oral route showed high inter-subject variability (CV >80%), consistent with the well-established challenge of gastrointestinal peptide degradation and first-pass metabolism.

This pharmacokinetic data has important implications for research design: studies using the oral route should account for large variability in exposure and consider measuring plasma peptide levels to confirm systemic delivery. Studies using SC administration will achieve more consistent and higher exposure, which is relevant when designing dose-response experiments in animal models.

Pharmacokinetics

The half-life of approximately 30-45 minutes by SC administration is consistent with what would be expected for a 1.8 kDa disulfide-stabilized peptide lacking PEGylation or other half-life extension modifications. 11 Endoproteases in plasma and interstitial fluid cleave the peptide backbone, and the resulting small fragments are filtered at the glomerulus. The disulfide bond provides some protection against reduction by thioredoxin systems in plasma, but overall the molecule is metabolically labile relative to larger proteins or synthetic small molecules.

From a research perspective, the short half-life has two practical implications. First, if the research question involves sustained receptor engagement, frequent dosing or continuous infusion in animal models will be required to maintain pharmacologically relevant concentrations. Second, sample timing in pharmacodynamic studies is critical: blood draws for downstream biomarkers (FFAs, glycerol, cAMP) should be obtained within the first 60-90 minutes post-administration to capture peak pharmacodynamic response.

The lack of formal protein binding data in the published literature is a gap. For a 1.8 kDa peptide with relatively high arginine content (and thus positive charge at physiological pH), non-specific binding to albumin and alpha-2-macroglobulin is possible. Researchers designing ex-vivo binding assays should include protein-containing buffers rather than assay in simple saline to approximate in-vivo conditions.

Purity and Verification

What a Credible CoA Should Contain

A certificate of analysis (CoA) from a reputable supplier should provide at minimum the following for HGH Fragment 176-191:

1. HPLC chromatogram with retention time and peak area percentage. Purity should be reported as "area %" of the main peak by reverse-phase HPLC (C18 column, UV detection at 214 nm). For research-grade material, >=98% is the expected specification; anything below 95% is marginal.

2. Mass spectrometry confirmation. The CoA should show the observed molecular ion matching the expected MW of 1817.1 Da within instrument tolerance (typically +/- 0.5 Da for single-quadrupole instruments, better for high-resolution MS). The presence of the correctly oxidized, disulfide-bonded species should be confirmed; a reduced (linear) form would show a mass 2 Da higher due to the two additional hydrogens.

3. Amino acid analysis or sequencing data (ideal but not always provided by commercial research vendors). At a minimum, the supplier should confirm the correct sequence by providing an MS/MS fragmentation table.

4. Water content (Karl Fischer titration). Lyophilized peptides typically contain 5-15% water by weight; if the CoA does not specify water content, the actual peptide content per vial may be lower than the stated nominal weight.

5. Residual solvents and endotoxin levels for any material intended for cell culture or in-vivo administration.

Independent Verification Approach

Researchers who need to verify purity independently before conducting in-vivo experiments should consider sending a small aliquot (0.1-0.2 mg) to an independent analytical chemistry laboratory for HPLC-MS analysis. Several academic core facilities and commercial contract labs (Eurofins, Pacific Biolabs) offer peptide purity analysis as a fee-for-service. 12

A common quality-control protocol for peptide research labs is to dissolve a small quantity of the incoming vial in LC-MS-grade water, dilute to approximately 0.1 mg/mL, and inject 10 microliters onto an analytical C18 column. Comparing the resulting chromatogram against the vendor CoA provides a quick cross-check. Any additional peaks exceeding 1-2% of total area warrant investigation and may indicate synthesis-related impurities (deletion sequences, protected amino acid carryovers, or oxidized methionine analogs) or degradation products from improper storage.

See our guide to reading peptide CoAs and supplier verification for a step-by-step walkthrough of the full verification process.

Dosage and Reconstitution

Important framing: All dose figures in this section are drawn directly from peer-reviewed preclinical and clinical trial literature. They are reported here for researchers designing experiments to align with or build on the existing evidence base. They do not represent recommendations for human administration. For a step-by-step reconstitution protocol, see our guide to reconstituting peptides. For the mathematics of preparing working concentrations, see our peptide dosage calculation guide.

Literature-Reported Research Doses

Rodent in-vivo studies have predominantly used doses in the range of 250-500 micrograms per kilogram per day by SC injection, administered once daily. 2 At 500 mcg/kg/day in a 250-gram rat, this corresponds to approximately 125 micrograms per animal per day. A 5 mg vial could support approximately 40 animal-days at this dose per rat, or around 40 daily treatments.

Clinical trial oral doses ranged from 250 mcg to 1 mg per day in Phase II studies. 3 SC doses in the pharmacokinetic study were reported at 1 mg per subject. These are literature-reported figures from regulated clinical research with full ethics board approvals; they are reproduced here for scientific context only.

In-vitro cell culture studies typically used concentrations of 1 nM to 100 nM in culture medium. For a standard 6-well plate experiment with 2 mL of medium per well, achieving 10 nM requires approximately 18 nanograms of peptide (given MW 1817 Da), meaning a single 5 mg vial provides far more material than would be consumed in cell-culture assays alone.

Reconstitution: Three Worked Examples

Example 1: Preparing a 1 mg/mL stock solution from a 5 mg vial. Add 5.0 mL of sterile bacteriostatic water (or 0.9% saline if using within 24-48 hours) to the lyophilized powder. Cap, and gently swirl without vortexing to avoid foaming. The resulting solution contains 1 mg/mL (1000 mcg/mL). This is a practical research stock concentration for in-vitro work. Aliquot into 0.5 mL fractions and store at -20 °C to avoid freeze-thaw degradation. Each freeze-thaw cycle can reduce peptide integrity by a few percent cumulatively; limiting cycles to <=3 is recommended practice in analytical chemistry guidance. 12

Example 2: Preparing a 500 mcg/mL solution for rodent SC injection (250 mcg/kg dose in a 250 g rat). Starting from the 1 mg/mL stock in Example 1, dilute 1:1 with sterile vehicle (0.9% saline or PBS) to yield 500 mcg/mL. For a 250 g rat dosed at 250 mcg/kg, the target dose is 62.5 mcg. At 500 mcg/mL, the injection volume is 62.5/500 = 0.125 mL (125 microliters), which is an appropriate SC injection volume for a rat. Prepare fresh dilutions daily or store refrigerated for a maximum of seven days.

Example 3: Preparing a 10 nM in-vitro working solution from the 1 mg/mL stock. MW = 1817.1 g/mol. 10 nM = 10 x 10-9 mol/L. Mass per liter = 10 x 10-9 x 1817.1 = 18.17 micrograms/L = 18.17 nanograms/mL. From a 1 mg/mL stock (= 1,000,000 ng/mL), a dilution factor of 1,000,000/18.17 = approximately 55,000-fold is needed. In practice: dilute 1 microliter of stock into 55 mL of culture medium, or perform serial dilutions (1:100 then 1:550) to manage pipetting accuracy. Use a fresh dilution for each experimental day to avoid concentration drift from adsorption to polypropylene surfaces.

Side Effects and Safety

Safety Profile from Clinical Trials

The Phase IIb clinical trial program provides the most systematic human safety data available for AOD-9604. In the 536-participant trial, the compound was reported to be well tolerated across all dose groups (0.25 mg, 0.5 mg, 1 mg oral daily). 3 The most commonly reported adverse events were mild and transient gastrointestinal symptoms (nausea, loose stools) occurring at slightly higher rates in the 1 mg group compared with placebo, consistent with the irritant potential of any peptide in concentrated oral doses. No serious adverse events (SAEs) were attributed to the study drug. Liver enzyme panels, kidney function tests, and hematology parameters showed no clinically meaningful changes from baseline in any active treatment group.

Critically, the absence of IGF-1 elevation means AOD-9604 does not carry the theoretical proliferative risk associated with full-length hGH or GH secretagogues that raise endogenous GH substantially. Elevated IGF-1 has been associated with increased risk of certain cancers in epidemiological studies, though causality remains debated. 6 AOD-9604's clean IGF-1 profile is therefore one of its more favorable safety features in the clinical literature.

Anti-Doping Status

AOD-9604 has been included on the World Anti-Doping Agency (WADA) Prohibited List under the category of Peptide Hormones, Growth Factors, and Related Substances. 13 Researchers studying this compound in athlete populations or using assay materials derived from sports medicine contexts should be aware of this classification. Institutional review boards covering sports research may require additional disclosure.

Potential Off-Target Effects in Preclinical Models

At doses substantially above those used in the clinical trials (reported as 10-100 times higher in some rodent studies), transient tachycardia has been observed, consistent with beta-3 AR stimulation in cardiac tissue, where beta-3 ARs are expressed at low levels. 9 This effect was not observed at clinically relevant doses. Researchers using high-dose animal experiments should include cardiovascular monitoring as a safety endpoint.

No genotoxicity, reproductive toxicity, or carcinogenicity studies have been published in the peer-reviewed literature for AOD-9604 as of 2026. The absence of published data in these categories is not equivalent to demonstrated safety; it represents a genuine gap in the preclinical dataset.

How It Compares

Positioning vs Sermorelin

Sermorelin and AOD-9604 target fundamentally different points in the GH axis. Sermorelin is a synthetic analog of the first 29 amino acids of endogenous GHRH; it stimulates pituitary somatotrophs to secrete GH in physiological pulses, which then raises IGF-1. 14 The downstream lipolytic effect of sermorelin is therefore indirect and requires an intact pituitary. In research models where GH secretion is impaired (hypophysectomized animals, aged rodents with somatotropic axis decline), sermorelin loses efficacy while AOD-9604 retains its direct adipocyte activity. This makes AOD-9604 the preferable tool when the research question specifically addresses peripheral adipocyte signaling rather than pituitary function.

Positioning vs Ipamorelin and GHRP-6

Ipamorelin and GHRP-6 are ghrelin-receptor agonists that stimulate pulsatile GH release with varying selectivity for other neuroendocrine axes (cortisol, prolactin). 15 Like sermorelin, their lipolytic effect is indirect and IGF-1-dependent over chronic dosing. For metabolic research designs requiring clean isolation of adipocyte lipase activation independent of systemic GH elevation, AOD-9604 offers a mechanistic precision that neither GHRP compound can match. However, for research into ghrelin receptor pharmacology, appetite regulation, or GH pulse dynamics, the GHRPs are clearly the more appropriate tools.

Positioning vs Tesamorelin

Tesamorelin (FDA-approved as Egrifta for HIV-associated lipodystrophy) is the most clinically validated peptide for visceral fat reduction in the growth-hormone axis space. 16 Its mechanism is GHRH-receptor agonism leading to GH secretion; it raises IGF-1 and must be used with monitoring for glucose impairment. As a prescription pharmaceutical with documented GMP manufacturing, tesamorelin represents the gold standard for visceral fat reduction pharmacology from a regulatory standpoint. AOD-9604 occupies the research niche below this: a non-prescription research reagent with a well-characterized but non-approved pharmacological profile, useful for mechanistic studies that do not require pharmaceutical-grade material.

Where to Buy

Apollo Peptide Sciences offers HGH Fragment 176-191 in a 5 mg lyophilized vial at $50.00. See our full Apollo Peptide Sciences HGH Fragment 176-191 product page for the current batch CoA, independent purity verification notes, and shipping and returns policy detail. The internal product page links to the affiliated vendor; we do not link affiliate URLs directly in editorial content.

When evaluating any supplier for this compound, the checklist below summarizes minimum acceptable standards:

• Batch-specific HPLC certificate with chromatogram image, not just a number
• Mass spectrometry confirmation showing the correct MW (1817.1 Da) for the disulfide-bonded form
• Purity >=98% area by RP-HPLC
• Physical address and contactable customer service for batch-specific inquiries
• Clear refund or replacement policy for out-of-specification material

Our supplier guide reviews 12 vendors in the research peptide space against these criteria and provides side-by-side pricing for the most commonly sourced compounds. For researchers new to peptide procurement, the guide also covers import regulations for major jurisdictions.

Open Research Questions

Despite a relatively mature literature base for a research peptide, several mechanistically important questions remain unresolved for HGH Fragment 176-191 as of 2026.

Definitive receptor identification. The beta-3 AR hypothesis is well-supported but not definitively proven using radioligand binding or genetic knockout studies. A clean beta-3 AR-null mouse experiment comparing AOD-9604's lipolytic effect to wild-type would resolve this question, but no such study has been published. Researchers with access to beta-3 AR knockout models are well positioned to address this gap.

Cartilage and joint biology. The Ghosh et al. chondroprotective data are intriguing but mechanistically uncharacterized. The receptor(s) mediating effects in chondrocytes are unknown, and it is unclear whether the effect is specific to the AOD-9604 sequence or shared with other hGH-derived peptides. Phase I/II clinical trials in knee OA have been discussed in the literature but peer-reviewed results have not been published.

CNS and appetite regulation. Intracerebroventricular studies showing appetite suppression at high doses have not been followed up with receptor pharmacology or CNS distribution studies. Whether the peptide crosses the blood-brain barrier at any dose remains formally unstudied.

Combination pharmacology. The lack of IGF-1 stimulation makes AOD-9604 a potentially interesting partner compound in metabolic research protocols alongside insulin sensitizers or GLP-1 receptor agonists. No formal combination pharmacology studies have been published.